SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
Revenue from operations climbed 13% to Rs. 886.87 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
Expands Davaindia network to 2,579 stores
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
The company reported free cash flow of Rs. 2,590 Mn for FY26
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated